AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9801884
Drug: Povidone-iodine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 4% solution
Trial: 7831637
Drug: Inhaled lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lignocaine (20 mg)
Trial: 28899262
Drug: Concurrent assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent assessment of misinformation narratives
Trial: 28209296
Drug: Intravenous mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mitomycin (12 mg/m2 on day 1) or intravenous cisplatin (60 mg/m2 on days 1 and 29), with intravenous fluorouracil (1000 mg/m2 per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Trial: 28209296
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (fluorouracil and cisplatin)
Trial: 26439877
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg Se as Se yeast) daily for 6 months
Trial: 17194267
Drug: Zonisamide (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (100-600 mg/day)
Trial: 12932067
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol and remifentanil
Trial: 12848597
Drug: lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine 10 mg once daily
Trial: 9483355
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (reviparin sodium, Clivarin) s.c. once daily with graduated elastic stockings (n = 359)
Trial: 8460391
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (10 mg/kg body weight) administered 12 hours and 1 hour prior to operation
Trial: 29247148
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg Q2W
Trial: 22769235
Drug: Intravenous alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alendronate (ALN) 900 µg every 4 weeks
Trial: 22769235
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (ALN) 35 mg once weekly
Trial: 26013711
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) insulin glargine in combination with intravenous (IV) insulin
Trial: 26013711
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) insulin (standard care control)
Trial: 23353610
Drug: Carbohydrate loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate loading with 18% carbohydrate beverage (375 mL between 9 pm and 12 pm, and 250 mL at 6:30 am)
Trial: 21207018
Drug: Isosorbide-SR 40
RxNorm normalized name: isosorbide dinitrate 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-SR 40 mg
Trial: 19273960
Drug: ASCs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCs treatment
Trial: 2905256
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 150 mg once daily
Trial: 31010570
Drug: Topical menthol
RxNorm normalized name: menthol Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical menthol at different concentrations (liquid and gel formulations)
Trial: 25245138
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interventions to increase PC and IM
Trial: 24093664
Drug: 20 mg/mL
RxNorm normalized name: urea 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/mL hyaluronic acid gel (VYC-20L)
Trial: 21756794
Drug: Implantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of compound artificial bone of HA-Bone cement
Trial: 19131469
Drug: Interactive weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interactive weekly automated telephone self-management support with nurse follow-up (ATSM)
Trial: 19131469
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group medical visits with physician and health educator facilitation (GMV)
Trial: 16359822
Drug: Estradiol challenge
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol challenge test (estradiolbenzoate 0.04 mg/kg, intramuscular injection)
Trial: 15650497
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg-60 mg daily for up to 19 weeks)
Trial: 11269568
Drug: A/L/Z combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/L/Z combination tablet after an overnight fast
Trial: 11269568
Drug: Abacavir 300
RxNorm normalized name: abacavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir 300 mg + Lamivudine 150 mg + Zidovudine 300 mg tablets after an overnight fast
Trial: 11269568
Drug: A/L/Z combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/L/Z combination tablet 5 minutes after a standardized high-fat breakfast
Trial: 2883988
Drug: H-I 42
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H-I 42 BS 50 mg
Trial: 2883988
Drug: H-I 42
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H-I 42 BS 100 mg
Trial: 2883988
Drug: H-I 42
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H-I 42 BS 200 mg
Trial: 2883988
Drug: H-I 42
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H-I 42 BS 400 mg
Trial: 2883988
Drug: H-I 42
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H-I 42 BS 400 mg vs Atenolol 50 mg
Trial: 31283891
Drug: Topical CHQ
RxNorm normalized name: CHQ
DrugBank: Chloroxine (DB01243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical CHQ 0.03% twice a day with carboxymethylcellulose (CMC) 0.5% three times a day
Trial: 31283891
Drug: Topical CMC
RxNorm normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical CMC 0.5% three times a day
Trial: 28864027
Drug: Tribendimidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine 400 mg plus ivermectin 200 μg/kg
Trial: 28864027
Drug: Tribendimidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine 400 mg plus oxantel pamoate 25 mg/kg
Trial: 28864027
Drug: Tribendimidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine 400 mg plus placebo (monotherapy)
Trial: 28864027
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg plus oxantel pamoate 25 mg/kg
Trial: 27755601
Drug: Primary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary prevention using misoprostol (600 mcg)
Trial: 24530023
Drug: Intraoperative intracameral
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraoperative intracameral injection of 1.2 mg/0.03 mL of triamcinolone acetonide
Trial: 24530023
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral prednisolone (1 mg/kg per day for 15 days, tapered over 2 weeks)
Trial: 22866670
Drug: autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous PRP injection with rehabilitation programme
Trial: 12431940
Drug: Flunkimmune (hypothetical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunkimmune (hypothetical drug)
Trial: 2924158
Drug: Hypnotic anesthesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic anesthesia
Trial: 518108
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg folic acid daily supplement from age 2 months
Trial: 31442204
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) in addition to conventional pharmacological treatment with Indacaterol-Glycopyrronium
Trial: 31442204
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment with Indacaterol-Glycopyrronium
Trial: 28919126
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (2 mSv)
Trial: 28919126
Drug: Standard-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT (≤8 mSv)
Trial: 8042760
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tramadol (100 mg loading dose, 12 mg/h for 24 h)
Trial: 8042760
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tramadol
Trial: 8042760
Drug: Repetitive bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive bolus administration (placebo infusion)
Trial: 8042760
Drug: Repetitive bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive bolus administration
Trial: 26437320
Drug: CC ointment
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC ointment (CCO)
Trial: 26437320
Drug: CC or
RxNorm normalized name: BD Syringe 10cc Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC or CC digests of collagen type I or III
Trial: 23626984
Drug: Zirconia implants
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zirconia implants supporting maxillary four-implant overdentures and mandibular three-implant overdentures; 28 implants total (maxilla: 16, mandible: 12)
Trial: 31944420
Drug: Zirconia implants
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zirconia implants
Trial: 18557003
Drug: Disc 'O'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disc 'O' Sit cushions used by 31 students in the treatment group for a 2-week period.
Trial: 15159224
Drug: Higher energy-dense
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher energy-dense entrée (7.32 kJ/g) served in the largest portion (900 g)
Trial: 15159224
Drug: Lower energy-dense
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower energy-dense entrée (5.23 kJ/g) served in the smallest portion (500 g)
Trial: 11454878
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² as a 1-hour infusion every 4 weeks
Trial: 11454878
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m²/d for 5 consecutive days every 3 weeks
Trial: 9741512
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (digoxin, diuretic, ACEI)
Trial: 9741512
Drug: Digoxin and
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin and diuretic therapy
Trial: 9741512
Drug: ACEI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI and diuretic therapy
Trial: 802630
Drug: Diuretic alone
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic alone
Trial: 3055943
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide (50 mg, tid)
Trial: 27418571
Drug: Heat-stressed dapagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stressed dapagliflozin 2.5-mg tablets
Trial: 27418571
Drug: Heat-stressed dapagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stressed dapagliflozin 10-mg tablets
Trial: 27418571
Drug: Heat-stressed dapagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stressed dapagliflozin 2.5-mg tablets (fed state)
Trial: 27418571
Drug: Heat-stressed dapagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stressed dapagliflozin 10-mg tablets (fed state)
Trial: 15309493
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material with iodine concentration of 300 mg/ml
Trial: 15309493
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material with iodine concentration of 370 mg/ml
Trial: 8092097
Drug: Beta-carotene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (60 mg/d)
Trial: 2690838
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with hydroxyethyl starch (HAES) and naftidrofuryl
Trial: 15475800
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg per day for 60 days
Trial: 11762668
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered 1 hour after acetaminophen ingestion
Trial: 11762668
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered 2 hours after acetaminophen ingestion
Trial: 11762668
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered 3 hours after acetaminophen ingestion
Trial: 31738834
Drug: Sirolimus (prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (prednisone ≤0.25 mg/kg/day)
Trial: 31738834
Drug: Prednisone (prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (prednisone ≤0.25 mg/kg/day)
Trial: 27159069
Drug: ACB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB with 10 mL lidocaine 1%
Trial: 20602760
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet
Trial: 20602760
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet in fed state
Trial: 20602760
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet given three times daily
Trial: 10959067
Drug: Tramadol 50-400
RxNorm normalized name: tramadol hydrochloride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50-400 mg/day
Trial: 11372002
Drug: Gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1200 mg/day
Trial: 9497506
Drug: Lovastatin 40-80
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40-80 mg at night
Trial: 8396100
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg daily for 3 days)
Trial: 8396081
Drug: Cloxacillin (dicloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin (dicloxacillin 12.5‐25 mg/kg daily for 7 days or flucloxacillin 250‐2000 mg/day for 7 days)
Trial: 30638985
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg/day)
Trial: 26894424
Drug: Hypnotic relaxation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic relaxation therapy (5 weekly sessions)
Trial: 21246186
Drug: Problem-solving counseling
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving counseling intervention (8 weekly sessions in groups of 8-10 adults)
Trial: 17302061
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicinal treatment
Trial: 29587297
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin treatment
Trial: 7755480
Drug: Captopril, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 75 mg a day (n = 8)
Trial: 2472126
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine maleate (100 to 200 mg/d)
Trial: 8180714
Drug: Health fair,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health fair, health risk information, follow-up screening, and incentive program (five $100 cash prizes for reducing serum cholesterol levels by 20% or below 5.17 mmol/L)
Trial: 762369
Drug: Dihydroergotoxine 6
RxNorm normalized name: dihydroergotoxine
DrugBank: Dihydroergotoxine (DB16602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine 6 mg daily
Trial: 762369
Drug: Dihydroergotoxine 3
RxNorm normalized name: dihydroergotoxine
DrugBank: Dihydroergotoxine (DB16602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine 3 mg daily
Trial: 24377218
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy of regulating qi circulation of fu-organ
Trial: 24377218
Drug: Shengxue Tongbian
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shengxue Tongbian Capsules
Trial: 19139435
Drug: Methotrexate 1
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 1 g/m2 over 24 hours with intrathecal injection and folinic acid rescue at 42 hours (MTX1 arm)
Trial: 19139435
Drug: Methotrexate 3
RxNorm normalized name: methotrexate 37.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3 g/m2 over 3 hours without intrathecal injection and folinic acid rescue at 24 hours (MTX3 arm)
Trial: 19139435
Drug: Methotrexate 1
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 1 g/m2 over 24 hours (MTX1 arm)
Trial: 19139435
Drug: Methotrexate 3
RxNorm normalized name: methotrexate 37.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3 g/m2 over 3 hours (MTX3 arm)
Trial: 17703713
Drug: Bridges intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bridges intervention (Standard Treatment plus Bridges)
Trial: 17703713
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment with Attention Control
Trial: 15073108
Drug: Ro 09‐4889
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 09‐4889 (1-200 mg)
Trial: 15073108
Drug: Ro 09‐4889
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 09‐4889 (20 mg)
Trial: 3136639
Drug: Adjunctive enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive enteral supplements
Trial: 31841106
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (generic from Panacea)
Trial: 31841106
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (innovator from Astellas)
Trial: 31165950
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg)
Trial: 28118938
Drug: PIKA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA vaccine classic regimen
Trial: 28118938
Drug: PIKA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA vaccine
Trial: 24834925
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 or 10 mg/kg every 4 weeks)
Trial: 16847400
Drug: R‐/S‐bicalutamide/HP55S 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐/S‐bicalutamide/HP55S 150 mg